Colorectal Cancer Screening: Stool DNA and Other Noninvasive Modalities

James R Bailey, Ashish Aggarwal, Thomas F Imperiale, James R Bailey, Ashish Aggarwal, Thomas F Imperiale

Abstract

Colorectal cancer screening dates to the discovery of precancerous adenomatous tissue. Screening modalities and guidelines directed at prevention and early detection have evolved and resulted in a significant decrease in the prevalence and mortality of colorectal cancer via direct visualization or using specific markers. Despite continued efforts and an overall reduction in deaths attributed to colorectal cancer over the last 25 years, colorectal cancer remains one of the most common causes of malignancy-associated deaths. In attempt to further reduce the prevalence of colorectal cancer and associated deaths, continued improvement in screening quality and adherence remains key. Noninvasive screening modalities are actively being explored. Identification of specific genetic alterations in the adenoma-cancer sequence allow for the study and development of noninvasive screening modalities beyond guaiac-based fecal occult blood testing which target specific alterations or a panel of alterations. The stool DNA test is the first noninvasive screening tool that targets both human hemoglobin and specific genetic alterations. In this review we discuss stool DNA and other commercially available noninvasive colorectal cancer screening modalities in addition to other targets which previously have been or are currently under study.

Keywords: Colorectal cancer; Colorectal cancer screening; Stool DNA; sDNA.

Figures

Fig. 1
Fig. 1
Timeline of noninvasive colorectal cancer screening modalities. CMS, Centers for Medicare & Medicaid Services; FOBT, fecal occult blood testing; sDNA, stool DNA; FIT, fecal immunochemical test.

References

    1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–2917. doi: 10.1002/ijc.25516.
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi: 10.3322/caac.21254.
    1. Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290–1314. doi: 10.1002/cncr.28509.
    1. Lockhart-Mummery JP, Dukes C. The precancerous changes in the rectum and colon. Surg Gynecol Obstet. 1928;36:591–596.
    1. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–767. doi: 10.1016/0092-8674(90)90186-I.
    1. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med. 1993;329:1977–1981. doi: 10.1056/NEJM199312303292701.
    1. Brenner H, Chang-Claude J, Seiler CM, Rickert A, Hoffmeister M. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med. 2011;154:22–30. doi: 10.7326/0003-4819-154-1-201101040-00004.
    1. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64:252–271. doi: 10.3322/caac.21235.
    1. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut. 2015;64:1637–1649. doi: 10.1136/gutjnl-2014-309086.
    1. Centers for Disease Control and Prevention (CDC) Vital signs: colorectal cancer screening test use: United States, 2012. MMWR Morb Mortal Wkly Rep. 2013;62:881–888.
    1. Gupta S, Sussman DA, Doubeni CA, et al. Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst. 2014;106:dju032. doi: 10.1093/jnci/dju032.
    1. Rex DK, Johnson DA, Anderson JC, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected] Am J Gastroenterol. 2009;104:739–750. doi: 10.1038/ajg.2009.104.
    1. Burt RW, Cannon JA, David DS, et al. Colorectal cancer screening. J Natl Compr Canc Netw. 2013;11:1538–1575.
    1. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627–637. doi: 10.7326/0003-4819-149-9-200811040-00243.
    1. Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134:1570–1595. doi: 10.1053/j.gastro.2008.02.002.
    1. DeBourcy AC, Lichtenberger S, Felton S, Butterfield KT, Ahnen DJ, Denberg TD. Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening. J Gen Intern Med. 2008;23:169–174. doi: 10.1007/s11606-007-0480-1.
    1. Shokar NK, Carlson CA, Weller SC. Informed decision making changes test preferences for colorectal cancer screening in a diverse population. Ann Fam Med. 2010;8:141–150. doi: 10.1370/afm.1054.
    1. Inadomi JM, Vijan S, Janz NK, et al. Adherence to colorectal cancer screening: a randomized clinical trial of competing strategies. Arch Intern Med. 2012;172:575–582. doi: 10.1001/archinternmed.2012.332.
    1. Zapka J, Klabunde CN, Taplin S, Yuan G, Ransohoff D, Kobrin S. Screening colonoscopy in the US: attitudes and practices of primary care physicians. J Gen Intern Med. 2012;27:1150–1158. doi: 10.1007/s11606-012-2051-3.
    1. Denberg TD, Melhado TV, Coombes JM, et al. Predictors of nonadherence to screening colonoscopy. J Gen Intern Med. 2005;20:989–995. doi: 10.1111/j.1525-1497.2005.00164.x.
    1. Day LW, Kwon A, Inadomi JM, Walter LC, Somsouk M. Adverse events in older patients undergoing colonoscopy: a systematic review and meta-analysis. Gastrointest Endosc. 2011;74:885–896. doi: 10.1016/j.gie.2011.06.023.
    1. U.S. Preventive Services Task Force. Guide to clinical preventive services: report of the US Preventive Services Task Force. 2nd ed. Baltimore: Williams & Wilkins; 1996.
    1. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med. 1993;328:1365–1371. doi: 10.1056/NEJM199305133281901.
    1. Libby G, Brewster DH, McClements PL, et al. The impact of population-based faecal occult blood test screening on colorectal cancer mortality: a matched cohort study. Br J Cancer. 2012;107:255–259. doi: 10.1038/bjc.2012.277.
    1. Scholefield JH, Moss SM, Mangham CM, Whynes DK, Hardcastle JD. Nottingham trial of faecal occult blood testing for colorectal cancer: a 20-year follow-up. Gut. 2012;61:1036–1040. doi: 10.1136/gutjnl-2011-300774.
    1. Shaukat A, Mongin SJ, Geisser MS, et al. Long-term mortality after screening for colorectal cancer. N Engl J Med. 2013;369:1106–1114. doi: 10.1056/NEJMoa1300720.
    1. Allison JE, Tekawa IS, Ransom LJ, Adrain AL. A comparison of fecal occult-blood tests for colorectal-cancer screening. N Engl J Med. 1996;334:155–159. doi: 10.1056/NEJM199601183340304.
    1. Church TR, Ederer F, Mandel JS. Fecal occult blood screening in the Minnesota study: sensitivity of the screening test. J Natl Cancer Inst. 1997;89:1440–1448. doi: 10.1093/jnci/89.19.1440.
    1. Lang CA, Ransohoff DF. Fecal occult blood screening for colorectal cancer: is mortality reduced by chance selection for screening colonoscopy? JAMA. 1994;271:1011–1013. doi: 10.1001/jama.1994.03510370063033.
    1. Ederer F, Church TR, Mandel JS. Fecal occult blood screening in the Minnesota study: role of chance detection of lesions. J Natl Cancer Inst. 1997;89:1423–1428. doi: 10.1093/jnci/89.19.1423.
    1. Allison JE, Fraser CG, Halloran SP, Young GP. Population screening for colorectal cancer means getting FIT: the past, present, and future of colorectal cancer screening using the fecal immunochemical test for hemoglobin (FIT) Gut Liver. 2014;8:117–130. doi: 10.5009/gnl.2014.8.2.117.
    1. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med. 2014;160:171. doi: 10.7326/M13-1484.
    1. Chiu HM, Lee YC, Tu CH, et al. Association between early stage colon neoplasms and false-negative results from the fecal immunochemical test. Clin Gastroenterol Hepatol. 2013;11:832–838.e2. doi: 10.1016/j.cgh.2013.01.013.
    1. de Wijkerslooth TR, Stoop EM, Bossuyt PM, et al. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. Am J Gastroenterol. 2012;107:1570–1578. doi: 10.1038/ajg.2012.249.
    1. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012;366:697–706. doi: 10.1056/NEJMoa1108895.
    1. VA Office of Research and Development. [Internet] Bethesda: U.S. National Library of Medicine; 2010. Nov 9, 2000. Colonoscopy versus fecal immunochemical test in reducing mortality from colorectal cancer (CONFIRM) [last updated 2015 Jul 23; cited 2015 Jul 30] Available from: .
    1. Guittet L, Bouvier V, Mariotte N, et al. Comparison of a guaiac and an immunochemical faecal occult blood test for the detection of colonic lesions according to lesion type and location. Br J Cancer. 2009;100:1230–1235. doi: 10.1038/sj.bjc.6604996.
    1. Cole SR, Young GP. Effect of dietary restriction on participation in faecal occult blood test screening for colorectal cancer. Med J Aust. 2001;175:195–198.
    1. Cole SR, Young GP, Esterman A, Cadd B, Morcom J. A randomised trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen. 2003;10:117–122. doi: 10.1258/096914103769011003.
    1. van Rossum LG, van Rijn AF, van Oijen MG, et al. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. Int J Cancer. 2009;125:746–750. doi: 10.1002/ijc.24458.
    1. Wong CK, Fedorak RN, Prosser CI, Stewart ME, van Zanten SV, Sadowski DC. The sensitivity and specificity of guaiac and immunochemical fecal occult blood tests for the detection of advanced colonic adenomas and cancer. Int J Colorectal Dis. 2012;27:1657–1664. doi: 10.1007/s00384-012-1518-3.
    1. Vogelstein B, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9:138–141. doi: 10.1016/0168-9525(93)90209-Z.
    1. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 1996;87:159–170. doi: 10.1016/S0092-8674(00)81333-1.
    1. Ahlquist DA, Harrington JJ, Burgart LJ, Roche PC. Morphometric analysis of the “mucocellular layer” overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol. 2000;31:51–57. doi: 10.1016/S0046-8177(00)80198-7.
    1. Ahlquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology. 2000;119:1219–1227. doi: 10.1053/gast.2000.19580.
    1. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001;93:858–865. doi: 10.1093/jnci/93.11.858.
    1. Syngal S, Stoffel E, Chung D, et al. Detection of stool DNA mutations before and after treatment of colorectal neoplasia. Cancer. 2006;106:277–283. doi: 10.1002/cncr.21558.
    1. Imperiale TF, Ransohoff DF, Itzkowitz SH, Turnbull BA, Ross ME Colorectal Cancer Study Group. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med. 2004;351:2704–2714. doi: 10.1056/NEJMoa033403.
    1. Ahlquist DA, Sargent DJ, Loprinzi CL, et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med. 2008;149:441–450. doi: 10.7326/0003-4819-149-7-200810070-00004.
    1. Zou H, Harrington JJ, Klatt KK, Ahlquist DA. A sensitive method to quantify human long DNA in stool: relevance to colorectal cancer screening. Cancer Epidemiol Biomarkers Prev. 2006;15:1115–1119. doi: 10.1158/1055-9965.EPI-05-0992.
    1. Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection. Am J Gastroenterol. 2008;103:2862–2870. doi: 10.1111/j.1572-0241.2008.02088.x.
    1. Ahlquist DA, Zou H, Domanico M, et al. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas. Gastroenterology. 2012;142:248–256. doi: 10.1053/j.gastro.2011.10.031.
    1. Lidgard GP, Domanico MJ, Bruinsma JJ, et al. Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia. Clin Gastroenterol Hepatol. 2013;11:1313–1318. doi: 10.1016/j.cgh.2013.04.023.
    1. Diehl F, Schmidt K, Durkee KH, et al. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology. 2008;135:489–498. doi: 10.1053/j.gastro.2008.05.039.
    1. Zou H, Taylor WR, Harrington JJ, et al. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology. 2009;136:459–470. doi: 10.1053/j.gastro.2008.10.023.
    1. Zou H, Allawi H, Cao X, et al. Quantification of methylated markers with a multiplex methylation-specific technology. Clin Chem. 2012;58:375–383. doi: 10.1373/clinchem.2011.171264.
    1. Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014;370:1287–1297. doi: 10.1056/NEJMoa1311194.
    1. Lansdorp-Vogelaar I, Kuntz KM, Knudsen AB, Wilschut JA, Zauber AG, van Ballegooijen M. Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. Ann Intern Med. 2010;153:368–377. doi: 10.7326/0003-4819-153-6-201009210-00004.
    1. Skally M, Hanly P, Sharp L. Cost effectiveness of fecal DNA screening for colorectal cancer: a systematic review and quality appraisal of the literature. Appl Health Econ Health Policy. 2013;11:181–192. doi: 10.1007/s40258-013-0010-8.
    1. Patel SS, Kilgore ML. Cost effectiveness of colorectal cancer screening strategies. Cancer Control. 2015;22:248–258.
    1. Exact Sciences. Exact Sciences provides update on strong launch trajectory of Cologuard [Internet] Madison: Exact Sciences; 2015. [cited 2015 Jun 25]. Available from: .
    1. Yang W, Lee DY, Ben-David Y. The roles of microRNAs in tumorigenesis and angiogenesis. Int J Physiol Pathophysiol Pharmacol. 2011;3:140–155.
    1. Koga Y, Yasunaga M, Takahashi A, et al. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res (Phila) 2010;3:1435–1442. doi: 10.1158/1940-6207.CAPR-10-0036.
    1. Wu CW, Ng SS, Dong YJ, et al. Detection of miR-92a and miR-21 in stool samples as potential screening biomarkers for colorectal cancer and polyps. Gut. 2012;61:739–745. doi: 10.1136/gut.2011.239236.
    1. Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58:1375–1381. doi: 10.1136/gut.2008.167817.
    1. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–325.
    1. Ahlquist DA, Taylor WR, Mahoney DW, et al. The stool DNA test is more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol. 2012;10:272–277.e1. doi: 10.1016/j.cgh.2011.10.008.
    1. Jin P, Kang Q, Wang X, et al. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm. J Gastroenterol Hepatol. 2015;30:830–833. doi: 10.1111/jgh.12855.
    1. Dickinson BT, Kisiel J, Ahlquist DA, Grady WM. Molecular markers for colorectal cancer screening. Gut. 2015;64:1485–1494. doi: 10.1136/gutjnl-2014-308075.
    1. Hoff G, Grotmol T, Thiis-Evensen E, Bretthauer M, Gondal G, Vatn MH. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT) Gut. 2004;53:1329–1333. doi: 10.1136/gut.2004.039032.
    1. Shastri YM, Loitsch S, Hoepffner N, et al. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study. Am J Gastroenterol. 2008;103:1496–1504. doi: 10.1111/j.1572-0241.2008.01824.x.
    1. Tonus C, Sellinger M, Koss K, Neupert G. Faecal pyruvate kinase isoenzyme type M2 for colorectal cancer screening: a meta-analysis. World J Gastroenterol. 2012;18:4004–4011. doi: 10.3748/wjg.v18.i30.4004.
    1. Haug U, Rothenbacher D, Wente MN, Seiler CM, Stegmaier C, Brenner H. Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer. 2007;96:1329–1334.
    1. Naumann M, Schaum B, Oremek GM, et al. Faecal pyruvate kinase type M2: a valid screening parameter for colorectal cancer? Preliminary results from a multicenter comparative study. Dtsch Med Wochenschr. 2004;129(34–35):1806–1807. doi: 10.1055/s-2004-829033.
    1. Uppara M, Adaba F, Askari A, et al. A systematic review and meta-analysis of the diagnostic accuracy of pyruvate kinase M2 isoenzymatic assay in diagnosing colorectal cancer. World J Surg Oncol. 2015;13:48. doi: 10.1186/s12957-015-0446-4.
    1. Centers for Medicare & Medicaid Services. Clinical laboratory fee schedule 2015 [Internet] Baltimore: Centers for Medicare & Medicaid Services; 2015. [cited 2015 Jul 30]. Available from: .
    1. Ahlquist DA. Multi-target stool DNA test: a new high bar for non-invasive screening. Dig Dis Sci. 2015;60:623–633. doi: 10.1007/s10620-014-3451-5.
    1. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut. 2014;63:317–325.
    1. Barton A. Blood test for colon cancer removes the ‘ick’ factor [Internet] Vancouver: The Globe and Mail; 2010. [cited 2015 Jul 30]. Available from:
    1. StatLabs [Internet] StatLabs; 2015. [cited 2015 Jul 30]. Available from: .
    1. Greegor DH. Diagnosis of large-bowel cancer in the asymptomatic patient. JAMA. 1967;201:943–945. doi: 10.1001/jama.1967.03130120051012.
    1. Hill MJ, Morson BC, Bussey HJ. Aetiology of adenoma: carcinoma sequence in large bowel. Lancet. 1978;1:245–247. doi: 10.1016/S0140-6736(78)90487-7.
    1. Barrows GH, Burton RM, Jarrett DD, Russell GG, Alford MD, Songster CL. Immunochemical detection of human blood in feces. Am J Clin Pathol. 1978;69:342–346.
    1. Centers for Medicare & Medicaid Services. Decision memo for screening immunoassay fecal-occult blood test (CAG-00180N) [Internet] Baltimore: Centers for Medicare & Medicaid Services; 2003. [cited 2015 Jul 30]. Available from: .

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera